Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silankang
- Development stage
- Phase 2
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Silankang is a live biotherapeutic product (LBP) consisting of a combination of four probiotic strains: *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. Developed by Hangzhou Yuanda Biopharmaceutical, it is formulated as a live bacterial preparation designed to restore the ecological balance of the intestinal microbiota. The mechanism of action involves the replenishment of beneficial anaerobic and facultative anaerobic bacteria that produce organic acids and bacteriocins to inhibit the growth of pathogenic organisms. *Bacillus cereus* specifically acts by consuming oxygen in the intestinal tract, thereby creating an anaerobic environment that facilitates the colonization and growth of *Bifidobacterium* and other beneficial species. Silankang is primarily indicated for gastrointestinal disorders associated with intestinal dysbiosis, including diarrhea and constipation, and is currently undergoing Phase II/III clinical evaluation in China for the treatment of functional constipation during pregnancy.
- Brand names
- Silankang
- Other names
- Quadruple Live Bacteria TabletsCombined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus tablets (live)
Beyond the preview
Go deeper on Silankang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Silankang.